Literature DB >> 17019735

Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.

Arianeb Mehrabi1, Arash Kashfi, Hamidreza Fonouni, Peter Schemmer, Bruno M Schmied, Peter Hallscheidt, Peter Schirmacher, Jurgen Weitz, Helmut Friess, Markus W Buchler, Jan Schmidt.   

Abstract

Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown etiology and a variable natural course. The authors present a comprehensive review of the literature on HEH with a focus on clinical outcome after different therapeutic strategies. All published series on patients with HEH (n = 434 patients) were analyzed from the first description in 1984 to the current literature. The reviewed parameters included demographic data, clinical manifestations, therapeutic modalities, and clinical outcome. The mean age of patients with HEH was 41.7 years, and the male-to-female ratio was 2:3. The most common clinical manifestations were right upper quadrant pain, hepatomegaly, and weight loss. Most patients presented with multifocal tumor that involved both lobes of the liver. Lung, peritoneum, lymph nodes, and bone were the most common sites of extrahepatic involvement at the time of diagnosis. The most common management has been liver transplantation (LTx) (44.8% of patients), followed by no treatment (24.8% of patients), chemotherapy or radiotherapy (21% of patients), and liver resection (LRx) (9.4% of patients). The 1-year and 5-year patient survival rates were 96% and 54.5%, respectively, after LTx; 39.3% and 4.5%, respectively, after no treatment, 73.3% and 30%, respectively, after chemotherapy or radiotherapy; and 100% and 75%, respectively, after LRx. LRx has been the treatment of choice in patients with resectable HEH. However, LTx has been proposed as the treatment of choice because of the hepatic multicentricity of HEH. In addition, LTx is an acceptable option for patients who have HEH with extrahepatic manifestation. Highly selected patients may be able to undergo living-donor LTx, preserving the donor pool. The role of different adjuvant therapies for patients with HEH remains to be determined. (c) 2006 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 17019735     DOI: 10.1002/cncr.22225

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  124 in total

1.  Multifocal epithelioid hemangioendothelioma presenting with hemoptysis.

Authors:  K S Madhusudhan; D N Srivastava; S Gamanagatti
Journal:  Indian J Pediatr       Date:  2010-06-08       Impact factor: 1.967

2.  Hepatic epithelioid hemangioendothelioma.

Authors:  Yueyi I Liu; Saghi S Brown; Arvand Elihu; C Andrew Bonham; Waldo Concepcion; Teri A Longacre; Aya Kamaya
Journal:  Dig Dis Sci       Date:  2010-10-30       Impact factor: 3.199

3.  Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report.

Authors:  Joseph Y Chang; Randolph S Marks; David M Nagorney; Schuyler O Sanderson; Sunanda Kane
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

4.  Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?

Authors:  Travis E Grotz; David Nagorney; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Scott Harmsen; David Mulligan; Justin Nguyen; Charles Rosen; Kaye M Reid-Lombardo
Journal:  HPB (Oxford)       Date:  2010-09-02       Impact factor: 3.647

5.  Radiographic and Histologic Findings of a Rare Liver Tumor-Hepatic Epithelioid Hemangioendothelioma.

Authors:  Noel Yarze; Joseph C Yarze
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

Review 6.  Imaging in liver transplantation.

Authors:  Settimo Caruso; Roberto Miraglia; Luigi Maruzzelli; Salvatore Gruttadauria; Angelo Luca; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

7.  Recurrent hepatic epithelioid hemangioendothelioma after orthotopic liver transplantation.

Authors:  Mary K Rude; Rao Watson; Jeffrey S Crippin
Journal:  Hepatology       Date:  2014-03-27       Impact factor: 17.425

8.  Two-stage treatment with hepatectomy and carbon-ion radiotherapy for multiple hepatic epithelioid hemangioendotheliomas.

Authors:  Shohei Komatsu; Takeshi Iwasaki; Yusuke Demizu; Kazuki Terashima; Osamu Fujii; Atsushi Takebe; Akihiro Toyokawa; Kazuhiro Teramura; Takumi Fukumoto; Yonson Ku; Nobukazu Fuwa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

9.  Long-term outcomes following liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005.

Authors:  Joel A Rodriguez; Natasha S Becker; Christine A O'Mahony; John A Goss; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2007-08-21       Impact factor: 3.452

10.  Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Authors:  Nicolas Penel; Isabelle Ray-Coquard; Christine Bal-Mahieu; Christine Chevreau; Axel Le Cesne; Antoine Italiano; Emmanuelle Bompas; Stéphanie Clisant; Brigitte Baldeyrou; Amélie Lansiaux; Yves-Marie Robin; Jacques-Olivier Bay; Sophie Piperno-Neumann; Jean-Yves Blay; Charles Fournier
Journal:  Target Oncol       Date:  2013-11-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.